Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track CELU with free AI briefings, catalyst countdowns, and dilution alerts.

CELU · Celularity Inc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$368,000 Cash on Hand

0.6mo Cash Runway

Follow CELU by email Get an email when CELU pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CELU, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Jul 2018 · Phase 1 · Results Expected · A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007
Registry primary completion date, not a results date
Mar 2017 · Phase 2 · Results Expected · A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PD
Registry primary completion date, not a results date
Oct 2016 · Phase 1 · Results Expected · Study of PDA-002 in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcers
Registry primary completion date, not a results date
Nov 2014 · Phase 1 · Results Expected · A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safe
Registry primary completion date, not a results date
Feb 2012 · Phase 2 · Results Expected · PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Aldesleukin	Metastatic HER2 Positive Gastroesophageal Junction	Phase 1/2 · NCT05207722	Terminated
PDA001	Rheumatoid Arthritis	Phase 2 · NCT01261403	Terminated
PDA-002	Peripheral Arterial Disease	Phase 2 · NCT02264288	Terminated
Human Placenta-Derived Cells PDA001 Intr	Stroke, Acute	Phase 2 · NCT01310114	Terminated
Fludarabine	Metastatic HER2 Positive Gastroesophageal Junction	Phase 1/2 · NCT05207722	Terminated
Allogeneic CD16-expressing Natural Kille	Metastatic HER2 Positive Gastroesophageal Junction	Phase 1/2 · NCT05207722	Terminated
Taniraleucel (CYNK-001)	Astrocytoma, Grade IV	Phase 1/2 · NCT05218408	Withdrawn

Also used in these trials (approved or third-party drugs, not CELU's own candidates): Mesna, Trastuzumab, Pembrolizumab, Cyclophosphamide, Human recombinant Interleukin-2 (rhIL-2), rhIL-2.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CELU holds $368,000 in cash and short-term investments (as of Mar 31, 2026) and burns about $1.8M/quarter from operations, an estimated runway of 0.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 52 · Elevated

Cash runway 1 months +40
Going-concern doubt in the latest 10-Q +15Management has evaluated the Company’s current financial position, liquidity, capital resources, and projected cash flows and has determined that there is substantial doubt about the Company’s ability to continue as a going concern. 10-Q, Sep 2026
Share count +22% in a year +7
Raised after last reported balance sheet (Sep 2026) -10

Recent financing filings on SEC EDGAR:

Sep 28, 2026 · Private placement (8-K Item 3.02) · 8-K
Dec 23, 2025 · Private placement (8-K Item 3.02) · 8-K
Oct 28, 2025 · Private placement (8-K Item 3.02) · 8-K
Aug 1, 2025 · Private placement (8-K Item 3.02) · 8-K
Jul 30, 2025 · Private placement (8-K Item 3.02) · 8-K
Jul 22, 2025 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CELU files for a raise →

Get the full CELU picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CELU and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z